Author

Elena Lomonosova

Washington University in St. LouisORCID 0009-0005-0970-4615Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:electrophysiology· 1

Frequent Co-Authors

Mary Margaret MulleniD· 4 shared Angela M. SchabiD· 3 shared Priyanka VermaiD· 3 shared Amanda J. CompadreiD· 2 shared Andrea R. HagemanniD· 2 shared Brooke E. SandersiD· 2 shared Carmen Sandoval· 2 shared Carolyn Kay McCourtiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Mary Margaret MullenORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

BioengineeringbioRxivPreprintMay 12, 2026

3D Printed Bioelectronic Scaffolds for Impedance-based Cytotoxicity Monitoring of In Vitro Cancer Models

Somtochukwu S. Okafor, Sandra K. Montgomery, Jae Park…·Alexandra L. Rutz

This paper introduces 3D printed bioelectronic scaffolds for impedance-based cytotoxicity monitoring in 3D cancer cell cultures, demonstrating their effectiveness in drug response assessment.

DOI 10.64898/2026.05.07.719019

electrophysiologyexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMar 4, 2026

Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers

Lindsey N Aubuchon, Deanna H. Wong, Natasha Ramakrishnan…·Priyanka Verma

This study shows that targeting ALC1 can enhance PARP inhibitor effectiveness in ovarian cancers, particularly in HRD and CCNE1-amplified tumors, with minimal toxicity.

DOI 10.64898/2025.12.04.692458

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 4, 2025

Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms

Elena Lomonosova, Megan Loeb, Kevin Rodriguez…·Mary Margaret Mullen

The paper identifies COPS5 as a therapeutic target for overcoming platinum resistance in ovarian cancer by inhibiting nucleotide excision repair and interstrand crosslink repair.

DOI 10.1101/2025.08.04.668450

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedMay 20, 2025

Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer

Angela M. Schab, Amanda J. Compadre, Rikki Drexler…·Mary Margaret Mullen

This study identifies phospho-RPA2 as a biomarker predicting response to platinum and PARP inhibitors in HR-proficient ovarian cancer, showing higher pathologic complete response and longer survival in pRPA2-High tumors.

11 citationstop 5%

humanimaging

𝕏 PostBluesky